Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611072 | 0.85 | EGFR (0.43) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL12410898 | 0.74 | EGFR (0.44) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL14643819 | 0.74 | EGFR (0.47) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL24996530 | 0.73 | EGFR (0.33) | EGFR | |
| SCHEMBL23421556 | 0.73 | EGFR (0.40) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL12938132 | 0.73 | NOS3 (0.34) | — | |
| SCHEMBL2611071 | 0.72 | EGFR (0.55) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL12703010 | 0.72 | NPC1 (0.50) | — | |
| SCHEMBL21477604 | 0.72 | GRM4 (0.31) | — | |
| SCHEMBL8874014 | 0.71 | EGFR (0.58) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2023-01-26 | — | — | US | disclosed |
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-08-17 | — | — | US | disclosed |
| EP-3838897-A2 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3553056-B1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
| EP-3553056-A1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen Targetrx, Inc. (CN) | 2019-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | MAP2K2, MAP2K5, MAP2K4 | EGFR 308/4885PIK3CD 275/4885PIK3CA 214/4885 |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | MAP2K2, MAP2K4, MAP2K5 | EGFR 294/4885PIK3CD 269/4885PIK3CA 216/4885 |
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | EGFR 3041/4885PIK3CD 1732/4885PIK3CA 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.